Answers are grounded in this paper and cite their sources.
IL-9 promotes airway hyperresponsiveness, eosinophilia, mast cell expansion, and antibody-mediated inflammation through interactions with mast cells, eosinophils, B cells, and airway and lung macrophages in models of allergic airway disease. IL-9 has increasingly been linked to asthma severity in patients. Early studies primarily focused on the differentiation of "classical" Th9 cells, which express IL-9 but not other type II cytokines. Recent research has identified additional populations of IL-9-secreting CD4 + T cells, including Th2-allergic (Th2A) cells and resident memory Th9 (Th9rm) cells. Despite IL-9 induction in classical Th9 effector cells being transient, Th2A and memory populations generate a recall IL-9 response upon repeated allergen exposure. Additionally, cytokine-driven bystander activation may prolong IL-9 production in various CD4 + T cell subsets. This review evaluates the transcriptional, metabolic, and cytokine-mediated signals that regulate the effector function of IL-9-secreting CD4 + T cell subsets in models of acute, chronic, and intermittent allergic airway disease. Given the heterogeneity of asthma phenotypes, identifying endotypes characterized by high levels of Th9 cells or IL-9 may improve therapeutic precision in asthma treatment.
No takes yet. Share an insight, caveat, or question.
Jackson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: